From the gut to the heart: probiotic therapy withand its potential role on diabetic cardiomyopathy in a murine model.

Abstract

BACKGROUND: We investigated whether the probiotic yeastconfers cardiometabolic protection and prevents diabetic cardiomyopathy by modulating inflammation, cardiac remodelling, cardiovascular function, and autonomic regulation. METHODS: Male C57BL/6 mice were allocated into four groups: Control (C), Diabetes (DM), Control+(CSb), and Diabetes+(DMSb). Diabetes was induced with intraperitoneal streptozotocin (STZ), and treatments (sterile water or) were administered orally for 8 weeks. Blood glucose, cytokines, and nitric oxide levels were measured, along with cardiac function via echocardiography and direct blood pressure recordings. RESULTS: reduced blood glucose and increased cardiac IL-10 in diabetic mice, restoring nitric oxide levels. These effects were associated to reduced collagen deposition, preventing vascular damage and ventricular fibrosis, and were accompanied by improved systolic/diastolic function and autonomic control. CONCLUSION: improved cardiac structure, function, and autonomic control in diabetic mice, supporting its potential as adjunct therapy for diabetic cardiomyopathy.